JP2013527164A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527164A5
JP2013527164A5 JP2013506767A JP2013506767A JP2013527164A5 JP 2013527164 A5 JP2013527164 A5 JP 2013527164A5 JP 2013506767 A JP2013506767 A JP 2013506767A JP 2013506767 A JP2013506767 A JP 2013506767A JP 2013527164 A5 JP2013527164 A5 JP 2013527164A5
Authority
JP
Japan
Prior art keywords
dosage form
polyoxyethylene
tadalafil
citrate
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013506767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527164A (ja
Filing date
Publication date
Priority claimed from US13/079,348 external-priority patent/US20110263606A1/en
Application filed filed Critical
Publication of JP2013527164A publication Critical patent/JP2013527164A/ja
Publication of JP2013527164A5 publication Critical patent/JP2013527164A5/ja
Pending legal-status Critical Current

Links

JP2013506767A 2010-04-26 2011-04-22 タダラフィルを含む固体経口剤形 Pending JP2013527164A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32796910P 2010-04-26 2010-04-26
US61/327,969 2010-04-26
US13/079,348 US20110263606A1 (en) 2010-04-26 2011-04-04 Solid oral dosage forms comprising tadalafil
US13/079,348 2011-04-04
PCT/IB2011/000882 WO2011135426A1 (en) 2010-04-26 2011-04-22 Solid oral dosage forms comprising tadalafil

Publications (2)

Publication Number Publication Date
JP2013527164A JP2013527164A (ja) 2013-06-27
JP2013527164A5 true JP2013527164A5 (enExample) 2014-04-10

Family

ID=44816306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013506767A Pending JP2013527164A (ja) 2010-04-26 2011-04-22 タダラフィルを含む固体経口剤形

Country Status (5)

Country Link
US (2) US20110263606A1 (enExample)
EP (1) EP2563346A4 (enExample)
JP (1) JP2013527164A (enExample)
CA (1) CA2797444A1 (enExample)
WO (1) WO2011135426A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
GB2497728A (en) 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2013109221A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic New effervescent formulations comprising sweetener composition
WO2013109230A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising tadalafil
WO2014027975A2 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel orally administered pharmaceutical formulations
US20150320677A1 (en) * 2012-08-17 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
WO2014027980A1 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral film formulations comprising dapoxetine and tadalafil
WO2014027982A2 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor
BR112015025859A2 (pt) * 2013-04-11 2017-07-25 Ctc Bio Inc forma de dosagem de filme contendo base livre de tadalafila contendo polímero à base de polietilenoglicol e/ou polímero à base de vinilpirrolidona como estabilizador de dispersão
US11116769B2 (en) 2013-04-11 2021-09-14 Ctc Bio, Inc. Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
HK1222796A1 (zh) * 2013-07-31 2017-07-14 因特根克斯公司 不含表面活性剂或多元醇的即时可湿性口服薄膜剂型
KR20150138671A (ko) * 2014-06-02 2015-12-10 에스케이케미칼주식회사 타달라필을 함유하는 구강 붕해 필름 및 이의 제조방법
ES2699160T3 (es) * 2014-06-24 2019-02-07 Wooshin Labottach Co Ltd Formulación de película de desintegración oral que contiene tadalafilo y procedimiento de preparación de la misma
KR101538985B1 (ko) * 2014-09-02 2015-07-24 주식회사 서울제약 타다라필 구강붕해필름 및 이의 제조방법
US20190133925A1 (en) 2016-03-11 2019-05-09 Intelgenx Corp. Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists
CZ2016570A3 (cs) * 2016-09-15 2018-03-28 Zentiva, K.S. Stabilní kompozice ODF obsahující těžce rozpustné terapeutické činidlo
CZ2017781A3 (cs) * 2017-12-05 2019-06-12 Zentiva, K.S. Těžko rozpustné terapeutická činidla,která patřící do BCS skupiny II nebo IV, suspendovaná v kapalné formulaci a/nebo v konečné nanovláknité struktuře
US20210137919A1 (en) * 2018-02-07 2021-05-13 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same
CN109157520B (zh) * 2018-09-07 2021-04-02 苏州科技城医院 他达拉非片剂及其制备方法
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
US12648905B2 (en) 2022-01-19 2026-06-09 Intelgenx Corp. Oral films with flavor entrapment
WO2023232215A1 (en) * 2022-06-02 2023-12-07 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and process for the preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
SV2002000055A (es) * 1999-04-30 2002-07-03 Lilly Icos Llc Articulos de manufactura ref. n0. 29342/36212 sv
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
PL1948615T3 (pl) * 2005-11-08 2012-04-30 Pfizer Ltd Pochodne pirazolu przydatne w leczeniu chorób ginekologicznych
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
ES2405787T3 (es) * 2007-04-25 2013-06-03 Teva Pharmaceutical Industries Ltd. Formas de dosificación solidas
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
MX2010004265A (es) * 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름

Similar Documents

Publication Publication Date Title
US20110263606A1 (en) Solid oral dosage forms comprising tadalafil
JP2015531377A5 (enExample)
EP3431075A1 (en) Edaravone dosage form
JP2012025755A5 (enExample)
JP2017536398A5 (enExample)
JP2015527395A5 (enExample)
RU2015154403A (ru) Офтальмическая наноэмульсионная композиция, содержащая циклоспорин и способ ее получения
JP2013529665A5 (enExample)
JP2016525572A5 (enExample)
JP2013514347A (ja) デクスイブプロフェン経皮ヒドロゲルの組成物
JP2015504924A5 (enExample)
AR103653A1 (es) Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen
RU2017101833A (ru) Орально распадающийся пленочный препарат, содержащий тадалафил, и способ его приготовления
US20100021538A1 (en) Pharmaceutical compositions containing heparin derivatives
JP2017508802A5 (enExample)
JP2015516418A5 (enExample)
CA2617140A1 (en) Pharmaceutical formulation with high stability and dissolution and manufacturing process
WO2016163403A1 (ja) 経口フィルム製剤
RU2017110076A (ru) Фармацевтическая композиция и способы
RU2014101990A (ru) Жидкая фармацевтическая композиция, включающая нитизинон
HRP20151051T1 (hr) Formulacije src/abl inhibitora
RU2017142563A (ru) Твердые дисперсии q10
AR078785A1 (es) Formulaciones de bazedoxifeno con antioxidantes
JP5734331B2 (ja) 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法
RU2013104252A (ru) Фармацевтическая композиция для пролонгированного высвобождения триметазидина